risperidone has been researched along with Alcohol Abuse in 17 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ninety-five patients with DSM-IV-TR diagnoses of schizophrenia and alcohol use disorder were randomized to 6 months of oral or LAI risperidone between 2005 and 2008." | 9.20 | Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. ( Brunette, MF; Buckley, P; Dawson, R; Green, AI; Hafez, H; Herz, M; Narasimhan, M; Noordsy, DL; O'Keefe, C; Sommi, RW; Steinbook, RM; Wallace, AE; Weeks, M, 2015) |
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 7.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| "A patient taking oral risperidone while using cocaine and alcohol presented with priapism shortly after long-acting, injectable risperidone was prescribed." | 7.75 | Priapism and risperidone. ( Koirala, S; Lippmann, S; Penagaluri, P; Smith, C, 2009) |
| "Clozapine is known to be effective in treating schizophrenia patients with comorbid alcohol use disorders (AUD)." | 7.74 | Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. ( Kim, D; Kim, JH; Marder, SR, 2008) |
| "Ninety-five patients with DSM-IV-TR diagnoses of schizophrenia and alcohol use disorder were randomized to 6 months of oral or LAI risperidone between 2005 and 2008." | 5.20 | Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. ( Brunette, MF; Buckley, P; Dawson, R; Green, AI; Hafez, H; Herz, M; Narasimhan, M; Noordsy, DL; O'Keefe, C; Sommi, RW; Steinbook, RM; Wallace, AE; Weeks, M, 2015) |
| " In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration." | 3.77 | Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. ( Crivera, C; Dirani, R; Kazis, LE; Qian, S; Ren, XS; Sikirica, M, 2011) |
| "A patient taking oral risperidone while using cocaine and alcohol presented with priapism shortly after long-acting, injectable risperidone was prescribed." | 3.75 | Priapism and risperidone. ( Koirala, S; Lippmann, S; Penagaluri, P; Smith, C, 2009) |
| "Clozapine is known to be effective in treating schizophrenia patients with comorbid alcohol use disorders (AUD)." | 3.74 | Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. ( Kim, D; Kim, JH; Marder, SR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Pathak, S | 1 |
| Jiang, Y | 1 |
| DiPetrillo, L | 1 |
| Todtenkopf, MS | 1 |
| Liu, Y | 1 |
| Correll, CU | 1 |
| Shah, UR | 1 |
| Vu, C | 1 |
| Thomas, R | 1 |
| Hartman, DW | 1 |
| Sharma, TR | 1 |
| Mohamed, S | 1 |
| Rosenheck, RA | 1 |
| Lin, H | 1 |
| Swartz, M | 1 |
| McEvoy, J | 1 |
| Stroup, S | 1 |
| Green, AI | 1 |
| Brunette, MF | 1 |
| Dawson, R | 1 |
| Buckley, P | 1 |
| Wallace, AE | 1 |
| Hafez, H | 1 |
| Herz, M | 1 |
| Narasimhan, M | 1 |
| Noordsy, DL | 1 |
| O'Keefe, C | 1 |
| Sommi, RW | 1 |
| Steinbook, RM | 1 |
| Weeks, M | 1 |
| Batki, SL | 1 |
| Petrakis, IL | 1 |
| Koirala, S | 1 |
| Penagaluri, P | 1 |
| Smith, C | 1 |
| Lippmann, S | 1 |
| Ren, XS | 1 |
| Crivera, C | 1 |
| Sikirica, M | 1 |
| Dirani, R | 1 |
| Qian, S | 1 |
| Kazis, LE | 1 |
| Celikyurt, IK | 1 |
| Kayir, H | 1 |
| Ulak, G | 1 |
| Erden, FB | 1 |
| Ulusoy, GK | 1 |
| Uzbay, TI | 1 |
| Ingman, K | 1 |
| Honkanen, A | 1 |
| Hyytiä, P | 1 |
| Huttunen, MO | 1 |
| Korpi, ER | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Ikeda, H | 1 |
| Yamamoto, M | 1 |
| Hashimoto, E | 1 |
| Saito, T | 1 |
| Kaplan, GB | 1 |
| McRoberts, RL | 1 |
| Smokler, HJ | 1 |
| Kim, JH | 1 |
| Kim, D | 1 |
| Marder, SR | 1 |
| Szigethy, EM | 1 |
| Schulz, SC | 1 |
| Snoddgrass, PL | 1 |
| Labbate, LA | 1 |
| Warnecke, M | 1 |
| Bahlmann, M | 1 |
| Soyka, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
1 review available for risperidone and Alcohol Abuse
| Article | Year |
|---|---|
[Alcohol hallucinosis].
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Dopamine; Hallucinations | 2003 |
3 trials available for risperidone and Alcohol Abuse
| Article | Year |
|---|---|
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzap | 2020 |
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi | 2015 |
Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.
Topics: Administration, Oral; Adult; Alcoholism; Antipsychotic Agents; Delayed-Action Preparations; Female; | 2015 |
13 other studies available for risperidone and Alcohol Abuse
| Article | Year |
|---|---|
Alcohol-induced psychotic disorder in a 42-year-old female patient.
Topics: Adult; Alcoholism; Antipsychotic Agents; Female; Humans; Psychoses, Substance-Induced; Risperidone | 2013 |
What is the right pharmacotherapy for alcohol use disorder in patients with schizophrenia?
Topics: Alcoholism; Antipsychotic Agents; Female; Humans; Male; Risperidone; Schizophrenia | 2015 |
How to best treat patients with schizophrenia and co-occurring alcohol use disorder.
Topics: Alcoholism; Antipsychotic Agents; Female; Humans; Male; Risperidone; Schizophrenia | 2015 |
Priapism and risperidone.
Topics: Adolescent; Alcoholism; Anemia, Sickle Cell; Antipsychotic Agents; Cocaine-Related Disorders; Humans | 2009 |
Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Topics: Adult; Aged; Alcoholism; Antipsychotic Agents; Comorbidity; Delayed-Action Preparations; Depression; | 2011 |
Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Central Nervous System Dep | 2011 |
Risperidone reduces limited access alcohol drinking in alcohol-preferring rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Rec | 2003 |
Oxcarbazepine, risperidone and atenolol overdose with benign outcome.
Topics: Adrenergic beta-Antagonists; Adult; Alcoholism; Anticonvulsants; Antipsychotic Agents; Atenolol; Bip | 2003 |
Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Baclofen; Bipolar Disord | 2004 |
Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia.
Topics: Adolescent; Adult; Alcoholism; Antipsychotic Agents; Clozapine; Diagnosis, Dual (Psychiatry); Female | 2008 |
Risperidone in comorbid borderline personality disorder and dysthymia.
Topics: Adult; Alcoholism; Antipsychotic Agents; Borderline Personality Disorder; Comorbidity; Dysthymic Dis | 1997 |
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dyskinesia, Drug-Induc | 1999 |
[Olfactory delusional syndrome and alcoholism].
Topics: Alcoholism; Combined Modality Therapy; Comorbidity; Delusions; Humans; Male; Middle Aged; Patient Ca | 2002 |